Atossa Therapeutics (ATOS) Competitors $0.64 -0.05 (-6.88%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.95%) As of 04/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. ETON, RNAC, TRDA, HRTX, DNA, TECX, UPB, ALLO, AMLX, and BNTCShould you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Eton Pharmaceuticals (ETON), Cartesian Therapeutics (RNAC), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), Ginkgo Bioworks (DNA), Tectonic Therapeutic (TECX), Upstream Bio (UPB), Allogene Therapeutics (ALLO), Amylyx Pharmaceuticals (AMLX), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. Atossa Therapeutics vs. Eton Pharmaceuticals Cartesian Therapeutics Entrada Therapeutics Heron Therapeutics Ginkgo Bioworks Tectonic Therapeutic Upstream Bio Allogene Therapeutics Amylyx Pharmaceuticals Benitec Biopharma Atossa Therapeutics (NASDAQ:ATOS) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Does the media refer more to ATOS or ETON? In the previous week, Atossa Therapeutics had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 9 mentions for Atossa Therapeutics and 7 mentions for Eton Pharmaceuticals. Atossa Therapeutics' average media sentiment score of 0.54 beat Eton Pharmaceuticals' score of 0.38 indicating that Atossa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, ATOS or ETON? Eton Pharmaceuticals has higher revenue and earnings than Atossa Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa TherapeuticsN/AN/A-$30.09M-$0.21-3.06Eton Pharmaceuticals$39.01M8.59-$940K-$0.15-83.33 Is ATOS or ETON more profitable? Atossa Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Atossa Therapeutics' return on equity of -35.74% beat Eton Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atossa TherapeuticsN/A -35.74% -33.51% Eton Pharmaceuticals -15.81%-36.29%-16.84% Which has more volatility and risk, ATOS or ETON? Atossa Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ATOS or ETON? 12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate ATOS or ETON? Atossa Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 989.49%. Eton Pharmaceuticals has a consensus price target of $27.67, suggesting a potential upside of 121.33%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ATOS or ETON? Atossa Therapeutics received 144 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. However, 65.77% of users gave Eton Pharmaceuticals an outperform vote while only 65.41% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformAtossa TherapeuticsOutperform Votes24265.41% Underperform Votes12834.59% Eton PharmaceuticalsOutperform Votes9865.77% Underperform Votes5134.23% SummaryEton Pharmaceuticals beats Atossa Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.99M$6.73B$5.54B$7.50BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-2.926.9923.2418.07Price / SalesN/A198.60361.2586.83Price / CashN/A65.6738.1634.64Price / Book0.885.926.493.99Net Income-$30.09M$142.37M$3.21B$247.18M7 Day Performance-7.71%-7.24%-4.91%-4.25%1 Month Performance-12.27%-10.45%-0.08%-6.87%1 Year Performance-69.40%-14.58%6.40%-3.73% Atossa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Therapeutics1.7948 of 5 stars$0.64-6.9%$7.00+989.5%-68.3%$82.99MN/A-2.928ETONEton Pharmaceuticals2.8057 of 5 stars$12.94-0.6%$27.67+113.8%+247.2%$347.03M$39.01M-58.8220Short Interest ↓RNACCartesian Therapeutics2.1723 of 5 stars$13.14-9.6%$42.14+220.7%-16.1%$340.39M$38.91M-0.2564Gap DownTRDAEntrada Therapeutics2.4575 of 5 stars$9.04-5.4%$25.67+183.9%-41.9%$339.86M$210.78M5.69110Analyst RevisionGap DownHRTXHeron Therapeutics3.215 of 5 stars$2.21-2.4%$5.67+157.0%-16.7%$335.89M$144.29M-12.25300Gap DownDNAGinkgo Bioworks0.5689 of 5 stars$5.71-6.8%$4.58-19.8%N/A$331.08M$227.04M-0.44640Gap UpTECXTectonic Therapeutic2.9653 of 5 stars$17.67-5.3%$77.75+340.1%N/A$329.68MN/A-3.00120UPBUpstream BioN/A$6.14-10.7%$56.50+820.9%N/A$329.09M$2.37M0.0038Lockup ExpirationALLOAllogene Therapeutics2.3514 of 5 stars$1.46-6.1%$9.29+538.4%-66.3%$316.12M$22,000.00-0.93310Gap DownAMLXAmylyx Pharmaceuticals2.6852 of 5 stars$3.54-3.4%$7.33+107.4%+33.5%$313.30M$87.37M-0.93200News CoverageGap DownBNTCBenitec Biopharma2.4228 of 5 stars$13.01-3.2%$24.43+87.8%+134.8%$304.98M$80,000.00-8.6120Short Interest ↑Analyst Revision Remove Ads Related Companies and Tools Related Companies ETON Alternatives RNAC Alternatives TRDA Alternatives HRTX Alternatives DNA Alternatives TECX Alternatives UPB Alternatives ALLO Alternatives AMLX Alternatives BNTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATOS Stock Free ATOS Stock Alerts